Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease. [PDF]
Martín-Gutiérrez N +5 more
europepmc +1 more source
Remsima® – the first biosimilar infliximab CT-P13
openaire +1 more source
Post-Marketing Pooled Safety Analysis for CT-P13 Treatment of Patients with Immune-Mediated Inflammatory Diseases in Observational Cohort Studies. [PDF]
Lee SJ +5 more
europepmc +1 more source
Correction to: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY). [PDF]
europepmc +1 more source
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials. [PDF]
Jørgensen KK +28 more
europepmc +1 more source
Effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting in patients with Crohn's disease or ulcerative colitis. [PDF]
Gheorghe C, Svoboda P, Mateescu B.
europepmc +1 more source
BACKGROUND AIMS: This study compared pharmacokinetics, symptomatic and endoscopic efficacy, safety, and immunogenicity of a subcutaneous formulation of the infliximab biosimilar CT-P13 (CT-P13 SC) vs intravenous CT-P13 (CT-P13 IV) in patients with ...
Byong Duk Ye +2 more
exaly +2 more sources

